Opioid manufacturers soon will be required to assess opioid efficacy changes during long-term use, but any labeling changes that may result likely are years away.
US FDA Commissioner Scott Gottlieb said the agency in "the next several months" will mandate that opioid manufacturers conduct randomized...




